WCG’s Lori Abrams Named PharmaVoice 100 DE&I Leader
Lori Abrams, WCG’s executive director of patient advocacy and diversity, has been named to the 2022 PharmaVoice 100 Top Industry Leaders for her efforts to diversify trial enrollment.
Selected as one of this year’s PharmaVoice DE&I Champions, Abrams is being recognized for her work at WCG to improve the diversity of trial populations and access for underserved groups by spurring culturally-appropriate conversations between patients, caregivers, communities and clinical research stakeholders.
“I am delighted and humbled to have been selected as a PharmaVoice 100 honoree,” Abrams said. “This award recognizes not just my efforts, but also the tireless dedication of our team, which is devoted to building trust in local communities and breaking down barriers so that all patients have an equal opportunity to get the high-quality healthcare they need and deserve.”
Abrams is joined by 14 other industry figures that were named DE&I Champions by PharmaVoice, including Scott Gray, president and CEO of Clincierge, Mary-Ann Etiebet, associate vice president for health equity at Merck, and Jennifer Gottlieb, global president and chief client officer for Real Chemistry.
The PharmaVoice 100 also includes leading entrepreneurs, innovators, legacy leaders, tech wizards and disrupters that had a big impact this year.